List of works - Robert Kralovics

5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines

scientific article published on 25 November 2020

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

scientific article published on 15 March 2009

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family.

scientific article published on 26 March 2008

A gain-of-function mutation of JAK2 in myeloproliferative disorders

scientific article (publication date: 28 April 2005)

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease

scientific article

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

scientific article

A polymorphism of the X-linked gene IDS increases the number of females informative for transcriptional clonality assays

scientific article published in April 2000

A reversible gene trap collection empowers haploid genetics in human cells

scientific article published on 25 August 2013

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis

scientific article published on 10 November 2008

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

scientific article published on March 2002

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

scientific article published on 4 May 2006

Allelic imbalance in CALR somatic mutagenesis

scientific article published on 8 January 2015

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

scientific article published on 4 August 2005

An RNA-Seq strategy to detect the complete coding and non-coding transcriptome including full-length imprinted macro ncRNAs

scientific article

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

scientific article published on 19 February 2014

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks

scientific article published on 11 January 2019

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

scientific article published on 7 August 2012

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

scientific article

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

scientific article

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

scientific article

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

scientific article

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms

scientific article published on 26 September 2014

Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders

scientific article published on 01 May 2003

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

scientific article

Congenital and inherited polycythemia.

scientific article

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia

scientific article

Co‐expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness

scientific article published in 2022

DNA curvature of the tobacco GRS repetitive sequence family and its relation to nucleosome positioning

scientific article published on April 1995

Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia

scientific article published on 23 April 2014

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

scientific article published on 27 May 2010

Development of a novel trans-lentiviral vector that affords predictable safety

scientific article published on July 2000

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

scientific article published on 29 April 2013

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

scientific article

Endemic polycythemia in Russia: mutation in the VHL gene.

scientific article published in January 2002

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

scientific article

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

scientific article published on 30 April 2014

Functional dissection of the TBK1 molecular network

scientific article

Genetic and epigenetic alterations of myeloproliferative disorders

scientific article published on 12 December 2012

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

scientific article published on 27 December 2016

Genetic basis of MPN: Beyond JAK2-V617F.

scientific article published on December 2013

Genetic complexity of myeloproliferative neoplasms.

scientific article published on 28 August 2008

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

scientific article

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

scientific article published on 29 April 2011

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

scientific article published on 07 January 2014

Haematopoietic progenitors and signal transduction in polycythaemia vera and primary thrombocythaemia.

scientific article

Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.

scientific article

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

scientific article published on 22 September 2011

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

scientific article

JAK inhibitor in CALR-mutant myelofibrosis

scientific article published on 01 March 2014

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

scientific article published on 23 December 2013

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans

scientific article published on 29 January 2016

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

scientific article published on 11 July 2016

Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis

scientific article published on 30 January 2014

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.

scientific article published on 22 August 2012

Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line

scientific article

Molecular basis and clonal evolution of myeloproliferative neoplasms

scientific article published on October 2013

Molecular basis and clonal evolution of myeloproliferative neoplasms

scientific article published on April 2010

Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms

scientific article published on January 2011

Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders

scientific article published in January 2005

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

scientific article

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation

scientific article published on 29 September 2014

Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

scientific article

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

scientific article

Overexpression of primary microRNA 221/222 in acute myeloid leukemia

scientific article

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

scientific article

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions

scientific article published on 18 November 2019

Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies

scientific article published on 17 June 2011

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

scientific article

Role of germline genetic factors in MPN pathogenesis

scientific article published on 21 August 2012

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

scientific article

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

scientific article published on 5 November 2007

Somatic mutations of calreticulin in myeloproliferative neoplasms

scientific article

Telomerase activity in plant cells.

scientific article published on August 1996

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

scientific article

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

scientific article published on 25 May 2006

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

scientific article published on 27 July 2014

The telomeric sequence is directly attached to the HRS60 subtelomeric tandem repeat in tobacco chromosomes

scientific article

The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia

scientific article

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium

scientific article published on 28 March 2012

p53 lesions in leukemic transformation

scientific article published on 01 February 2011

β Thalassemia major due to acquired uniparental disomy in a previously healthy adolescent.

scientific article

List of works by Robert Kralovics

5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family.

A gain-of-function mutation of JAK2 in myeloproliferative disorders

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

A polymorphism of the X-linked gene IDS increases the number of females informative for transcriptional clonality assays

A reversible gene trap collection empowers haploid genetics in human cells

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Allelic imbalance in CALR somatic mutagenesis

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

An RNA-Seq strategy to detect the complete coding and non-coding transcriptome including full-length imprinted macro ncRNAs

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms

Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

Congenital and inherited polycythemia.

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia

Co‐expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness

DNA curvature of the tobacco GRS repetitive sequence family and its relation to nucleosome positioning

Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Development of a novel trans-lentiviral vector that affords predictable safety

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Endemic polycythemia in Russia: mutation in the VHL gene.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

Functional dissection of the TBK1 molecular network

Genetic and epigenetic alterations of myeloproliferative disorders

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

Genetic basis of MPN: Beyond JAK2-V617F.

Genetic complexity of myeloproliferative neoplasms.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Haematopoietic progenitors and signal transduction in polycythaemia vera and primary thrombocythaemia.

Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

JAK inhibitor in CALR-mutant myelofibrosis

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.

Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line

Molecular basis and clonal evolution of myeloproliferative neoplasms

Molecular basis and clonal evolution of myeloproliferative neoplasms

Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms

Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation

Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

Overexpression of primary microRNA 221/222 in acute myeloid leukemia

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions

Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

Role of germline genetic factors in MPN pathogenesis

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Somatic mutations of calreticulin in myeloproliferative neoplasms

Telomerase activity in plant cells.

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity

The telomeric sequence is directly attached to the HRS60 subtelomeric tandem repeat in tobacco chromosomes

The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium